Accessibility Menu
Arrow-Thin-Down
S&P 500
6,672.57
-1.5%
-103.23
Arrow-Thin-Down
DJI
46,677.85
-1.6%
-739.42
Arrow-Thin-Down
NASDAQ
22,311.98
-1.8%
-404.16
Arrow-Thin-Down
Bitcoin
$70,423.00
-0.4%
-$268.68
Arrow-Thin-Down
AMZN
$209.42
-1.5%
-$3.23
Arrow-Thin-Down
GOOG
$303.23
-1.7%
-$5.19
Arrow-Thin-Down
META
$638.34
-2.5%
-$16.52
Arrow-Thin-Down
MSFT
$401.93
-0.7%
-$2.95
Arrow-Thin-Down
NVDA
$183.18
-1.5%
-$2.85
Arrow-Thin-Down
TSLA
$395.69
-3.0%
-$12.13
Most Active StocksDaily Stock GainersDaily Stock Losers

Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors

Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations.

By Motley Fool YouTube – Mar 5, 2026 at 4:05PM EST

Key Points

  • Novo Nordisk’s Kagrama showed less weight loss than Eli Lilly’s Zepbound in a key 84-week trial.
  • The setback could pressure Novo’s obesity growth outlook until full data and strategy updates emerge.

A surprising obesity trial result has shaken confidence in Novo Nordisk (NVO 2.05%) and sharpened the spotlight on Eli Lilly (LLY 1.93%) in this fiercely competitive GLP‑1 race. Watch the video below to see what it could mean for investors.

*This video was published on Feb.24, 2026.

Read Next

Stocks Mentioned

Novo Nordisk Stock Quote
Novo Nordisk
NYSE: NVO
$38.05
(-2.01%)-$0.78
Eli Lilly Stock Quote
Eli Lilly
NYSE: LLY
$978.66
(-2.12%)-$21.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services